Storia in 4 fonti

FULC Stock Crashes After Hours: What Investors Need To Know - Fulcrum Therapeutics (NASDAQ:FULC)

Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.

Raccontata da

biopharmadive.com

benzinga.com

endpoints.news

economictimes.indiatimes.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo16 h fa

FULC Stock Crashes After Hours: What Investors Need To Know - Fulcrum Therapeutics (NASDAQ:FULC)

Fulcrum Therapeutics discontinues pociredir on FDA ban of PRC2-targeting therapies for malignancy risks; stock crashes 49.69%. Clinical-stage safety risks can destroy pipeline value even with $333M cash, forcing M&A review and signaling sector headwinds.

originale

Timeline cronologica

martedì 2 giugno 2026·biopharmadive.com
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.
martedì 2 giugno 2026·benzinga.com
FULC Stock Crashes After Hours: What Investors Need To Know - Fulcrum Therapeutics (NASDAQ:FULC)
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.

FULC Stock Crashes After Hours: What Investors Need To Know - Fulcrum Therapeutics (NASDAQ:FULC)

Confronto fonti

FULC Stock Crashes After Hours: What Investors Need To Know - Fulcrum Therapeutics (NASDAQ:FULC)

Timeline cronologica

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

FULC Stock Crashes After Hours: What Investors Need To Know - Fulcrum Therapeutics (NASDAQ:FULC)

US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit

Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit

US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns